Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT.
Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO.
On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States.
Rival Eli Lilly (LLY.N), opens new tab has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound.
"It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen.
Novo has also applied this year for approval in Europe and Japan.
Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
15 minutes ago
- The Independent
Molly-Mae shares parenting struggle after Bambi bites another child at nursery
Molly-Mae Hague disclosed that her two-year-old daughter, Bambi, is part of a "biting pandemic" at her nursery. The influencer was informed by the nursery that Bambi has been biting other children. Hague expressed uncertainty about how to manage Bambi's behaviour, questioning whether to give her ice cream as a treat. She pondered if rewarding Bambi would encourage the behaviour or if drawing attention to it might be counterproductive, believing Bambi might be seeking a reaction. Watch the video in full above.
Scottish Sun
16 minutes ago
- Scottish Sun
I'm A Celeb winner admits using fat jab Mounjaro in candid interview – before issuing warning to other users
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) ACTOR Christopher Biggins has revealed he is using weight loss jab Mounjaro after having surgery on his knee. The panto star, 76, said: "I'm on Mounjaro… and I think it's good. Sign up for the Entertainment newsletter Sign up 1 Christopher Biggins has revealed he is using weight loss jab Mounjaro after having surgery on his knee Credit: Getty "I mean, I had a new knee put in, and I needed to lose weight because of the pressure on the knee." Biggins also claimed that "they're now finding out that this drug can cure a lot of other things" and added that "we don't know the side effects" of it yet. Weight loss jabs have been hailed as transformative by health leaders. The phased NHS roll-out of Mounjaro to patients in England started in June for people with a body mass index (BMI) over 40 and at least four co-morbidities. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. A number of celebrities have used medication, such as Ozempic, in a bid to control their weight, including former X Factor judge Sharon Osbourne. Wegovy and Ozempic are semaglutide drugs, while Mounjaro is another weight loss treatment called tirzepatide. Chef Heston Blumenthal recently warned that weight loss drugs will have a negative effect on the food industry.
BreakingNews.ie
16 minutes ago
- BreakingNews.ie
Row could collapse Cityjet rescue plans, court hears
A row over demands by contractors involving a potential investor in the refinancing of debt-ridden airline Cityjet, over proposed upfront payment terms for future maintenance work, could collapse rescue plans for the company which is currently in examinership, the High Court was told on Monday. Now the joint examiners to the carrier, Kieran Wallace and Andrew O'Leary, of specialist firm Interpath Advisory, are to ask the High Court on Wednesday for declarations that the attempted modification of maintenance contracts is invalid. Advertisement Barrister Stephen Byrne, counsel for the examiners, told Ms Justice Eileen Roberts that the effect of the proposed contractual amendments would have a material impact on Cityjet's ability to continue in examinership. Mr Wallace, in written evidence grounding the application, told Judge Roberts that the new demands could cause the examinership to fail. The court granted the joint examiners short service to bring a notice of motion regarding the new issues before the court on Wednesday. Cityjet's sole shareholder, Strategic Alliance of Regional Airlines (SARA), which itself is 80 per cent owned by Air Investment Valencia (AIV), has significant service contracts with sister entities and subsidiaries of SARA. The court heard that a key condition for the joint examiners to any reinvestment by the shareholder entities was a renegotiation of the company's various maintenance contracts in order to facilitate the survival of the company, as outlined by the joint examiners and an independent expert. Advertisement Mr Wallace stated that since his and Mr O'Leary's appointment, they have had regular engagement with certain shareholder entities in respect of potential reinvestment in the company as outlined in an earlier report to the High Court. He said it had become clear that the SARA shareholder entities would not make sufficiently significant concessions on contracts such as would be required to ensure a reasonable prospect of the survival of Cityjet as a going concern. Demands had been made by the contractors for payments to be made up front on a monthly basis with almost immediate effect. Mr Wallace said he and Mr O'Leary had decided to pursue alternative investment proposals from other interested parties, and another investment proposal had already been agreed and entered into by the company. Mr Byrne said that in correspondence with SARA legal representatives, the joint examiners had stated their view it was impermissible for any contracts to be varied. The matter comes up again before Mr Justice Quinn who initially appointed the joint examiners.
